Baseline characteristics for HSJ, control and Denmark (without HSJ) in the preintervention period, N = 289.045. by Eva Rydahl (6260771)

Subjects:

Change in maternal characteristics during 2003–2017, HSJ and control. by Eva Rydahl (6260771)

Subjects:

Cesarean section. by Eva Rydahl (6260771)

Subjects:

Flow chart of study participants. by Eva Rydahl (6260771)

Subjects:

Timeseries analyses HSJ trend before- and during intervention. by Eva Rydahl (6260771)

Subjects:

Absolute numbers among CS groups. by Eva Rydahl (6260771)

Subjects:

HSJ and controls stratified by timing for CS and parity. by Eva Rydahl (6260771)

Subjects:

Concurrent mixed methods design diagram. by Esario IV Daguman (21474116)

Subjects:

Outcomes and data gathering timeline. by Esario IV Daguman (21474116)

Subjects:

The guiding map. by Esario IV Daguman (21474116)

Subjects:

The RehaGait® system. by Johanna Rydja (12300797)

“…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”

Flow chart of included patients and dropouts. by Johanna Rydja (12300797)

“…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”

Dataset of the analyzed data. by Johanna Rydja (12300797)

“…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”

Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

“…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”

Table 1_Higher oxidative balance score is associated with a decreased risk of infertility: an analysis of NHANES 2013–2020.docx by Mingjun Ma (11518765)

Data Sheet 1_A synonymous mutation of rs1137070 cause the mice Maoa gene transcription and translation to decrease.pdf by Kai Xin Li (19696741)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Table 1_Fertilization decreases the effect of ammonium nitrogen on microorganisms in Chinese Carex tibetikobresia meadows during rest-grazing.docx by Xuanbo Zhou (19374205)